Published On: Tue, Apr 17th, 2018

Bristol-Myers Squibb (BMY) Pulled Back On Study Results

- (BMY) announced Monday morning that its Phase 3 , of Opdivo 3 mg/kg plus low-dose Yervoy in first-line advanced non-small cell lung cancer patients reduced the risk of death by 42% versus chemotherapy alone.

About the Author

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>